Bültmann R, Klebroff W, Starke K
Pharmakologisches Institut, Freiburg i.Br., Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):196-201. doi: 10.1007/s002109900049.
The possible existence of a contraction-mediating P2-receptor for uracil nucleotides was investigated in the rat vas deferens. In order to minimize breakdown of nucleotides, Evans blue was used as an inhibitor of ectonucleotidases. UTP was degraded by rat vas deferens tissue, and the degradation was inhibited by Evans blue (100 microM). In the absence of other drugs, UTP and UDP elicited marginal contractions. Evans blue (100 microM) greatly enhanced contractions elicited by the uracil nucleotides. When the medium contained alpha,beta-MeATP (100 microM) in addition to Evans blue in order to desensitize contraction-mediating P2X1-receptors, responses to UTP and UDP were not changed; in contrast, responses to alpha,beta-MeATP were virtually abolished and contractions elicited by ATP and ADP were greatly reduced; EC50 values were 122 microM for UTP and 58 microM for ATP under these conditions. The P2-receptor antagonist suramin attenuated contractions elicited by UTP (320 microM) and alpha,beta-MeATP (32 microM) in the presence of Evans blue; pyridoxalphosphate-6-azophenyl-2',5'-disulphonate (iso-PPADS) also reduced responses to alpha,beta-MeATP but, at up to 100 microM, did not alter contractions elicited by UTP. Incubation of vasa deferentia in nominally calcium-free medium almost abolished the response to alpha,beta-MeATP (32 microM), while a major part of the contraction elicited by UTP (320 microM) was preserved. In the presence of Evans blue and alpha,beta-MeATP, prior addition of UDP (3200 microM) or ATP (320 microM), without washout, markedly reduced the response to UTP (320 microM); UTP and ATP also reduced the response to UDP; in contrast, prior addition of UTP or UDP did not alter the contraction to ATP. The results demonstrate the existence of a contraction-mediating, uracil nucleotide-sensitive P2Y-receptor in rat vas deferens, distinct from the P2X1-receptor. Pharmacological analysis indicates that it is P2Y2.
在大鼠输精管中研究了尿嘧啶核苷酸的收缩介导性P2受体的可能存在情况。为了尽量减少核苷酸的分解,使用伊文思蓝作为外核苷酸酶的抑制剂。UTP被大鼠输精管组织降解,且这种降解被伊文思蓝(100微摩尔)抑制。在没有其他药物的情况下,UTP和UDP引起轻微收缩。伊文思蓝(100微摩尔)极大地增强了尿嘧啶核苷酸引起的收缩。当培养基中除了伊文思蓝之外还含有α,β-甲基ATP(100微摩尔)以使收缩介导性P2X1受体脱敏时,对UTP和UDP的反应没有变化;相反,对α,β-甲基ATP的反应几乎完全消失,且ATP和ADP引起的收缩大大减少;在这些条件下,UTP的半数有效浓度(EC50)值为122微摩尔,ATP为58微摩尔。P2受体拮抗剂苏拉明在有伊文思蓝存在的情况下减弱了UTP(320微摩尔)和α,β-甲基ATP(32微摩尔)引起的收缩;磷酸吡哆醛-6-偶氮苯基-2',5'-二磺酸盐(异-PPADS)也降低了对α,β-甲基ATP的反应,但在高达100微摩尔时,并未改变UTP引起的收缩。在名义上无钙的培养基中孵育输精管几乎消除了对α,β-甲基ATP(32微摩尔)的反应,而UTP(320微摩尔)引起的收缩的主要部分得以保留。在有伊文思蓝和α,β-甲基ATP存在的情况下,预先加入UDP(3200微摩尔)或ATP(320微摩尔),不进行洗脱,显著降低了对UTP(320微摩尔)的反应;UTP和ATP也降低了对UDP的反应;相反,预先加入UTP或UDP并未改变对ATP的收缩反应。结果表明,在大鼠输精管中存在一种收缩介导性、对尿嘧啶核苷酸敏感的P2Y受体,与P2X1受体不同。药理学分析表明它是P2Y2。